Print Page Print Page  |  RSS Feeds RSS Feeds  |  E-mail Alerts E-mail Alerts  |  IR Contacts IR Contacts  |  Financial Tear Sheet Financial Tear Sheet

This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
09/22/17Delcath Issues Letter to Shareholders
NEW YORK, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update and rationale for the Company’s recent actions to preserve access to capital. The full text of the Letter, which has also been posted to the Company's website,... 
Printer Friendly Version
09/19/17Data on Delcath’s CHEMOSAT System Presented at CIRSE Annual Meeting
NEW YORK, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the results of a single institution study were presented at the Cardiology and Interventional Radiology of Europe (CIRSE) annual meeting, held in Copenhagen, Denmark on September 16-20, 2017. The study, Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second Generation (... 
Printer Friendly Version
09/14/17Delcath Announces Accelerated Listing on OTCQB
NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that after conversations with both Nasdaq and OTC Markets, the Company is able to effect the change in listing to the OTC Markets more quickly than anticipated.  The Company's common stock will commence trading on the OTCQB on September 15, 2017 under the symbol "DCTH". About Delcath Systems Delcath ... 
Printer Friendly Version
09/13/17Delcath Announces Relisting on OTCQB
Company to Ensure Orderly Transition from NASDAQ to OTC Market NEW YORK, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that its Board of Directors has approved the voluntary delisting from NASDAQ. As a result of the shareholder non-approval of its reverse stock split last week by the requisite vote required under Delaware law, the Company does not meet the r... 
Printer Friendly Version
09/01/17Delcath Issues Letter to Stockholders
NEW YORK, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:DCTH) (the "Company"), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update and reiteration of the Board’s recommendation regarding the Company’s proposed reverse stock split. The full text of the Letter, which has als... 
Printer Friendly Version
08/29/17Delcath Announces Medical University of Hannover in Germany Celebrates 100th CHEMOSAT Treatment
NEW YORK, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, congratulates the team at the Medical University of Hannover Hospital on their performance of the hospital’s 100th percutaneous hepatic perfusion (PHP®) procedure with CHEMOSAT®. The Hannover team, led by Professor Dr. Frank Wacker, Director of the Institute for Diagnostic and Interventional Radiology and Professor... 
Printer Friendly Version
08/28/17Delcath Announces Agreement for Extinguishment of Convertible Notes with Majority Holder
Agreement Contingent upon Shareholder Vote in Favor of the Proposed Reverse Stock Split   Voting Deadline Extended to September 7, 2017 NEW YORK, Aug. 28, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that the Company has negotiated an agreement for the extinguishment of its 2016 Convertible Notes from the holder of the majority of the Notes.  The transaction is cont... 
Printer Friendly Version
08/22/17Delcath Systems, Inc. Announces Extension of Expiration Date of its Consent Solicitation and Ability to Change Consent Once Voted
NEW YORK, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH) (the “Company”) announced today that the deadline for its current Consent Solicitation (the “Consent Solicitation”), currently set to expire at 5:00 p.m. Eastern Time, on August 28, 2017, has been extended until September 7, 2017 at 5:00 p.m. Eastern Time to allow more opportunity for stockholders to submit consents on the proposal described in the Company’s definitive proxy statement filed with the Securities and ... 
Printer Friendly Version
08/08/17Delcath Announces Second Quarter 2017 Financial Results
Company Comments on Consent Proposal; Provides Corporate Update NEW YORK, Aug. 8, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2017. Highlights from the second quarter of 2017 and recent weeks include: Revenue for the second quarter of 2017 increased 20% to $0.6 million from $0.5 million in the pri... 
Printer Friendly Version
06/05/17Delcath Systems, Inc. Announces Adjournment of Annual Meeting Meeting Scheduled to Reconvene on June 16
NEW YORK, June 05, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH) (the “Company”) announced today that its 2017 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled for June 5, 2017, was convened and adjourned, without any business being conducted. The Annual Meeting has been adjourned until Friday, June 16, 2017 to allow more opportunity for stockholders to vote on all proposals described in the Company’s definitive proxy statement filed with the Securities and Excha... 
Printer Friendly Version
05/09/17Delcath Announces First Quarter 2017 Financial Results
NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three months ended March 31, 2017. Highlights for the first quarter of 2017 and recent weeks include: First quarter 2017 revenue of $0.74 million, an increase of 100% compared with revenue of $0.37 million in prior year quarter;  CHEMOSAT treatment milestone set by SPIRE ... 
Printer Friendly Version
04/27/17Delcath Issues Letter to Stockholders
NEW YORK, April 27, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:DCTH) (the "Company"), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update. The full text of the Letter, which has also been posted to the Company's website, is as follows. Dear Shareholders: The development of on... 
Printer Friendly Version
04/18/17Spire Southampton Hospital in UK Celebrating Over 100 CHEMOSAT Treatments
NEW YORK, April 18, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, commended Spire Southampton Hospital on the performance of over 100 percutaneous hepatic perfusion (PHP®) procedures with CHEMOSAT®. PHP with Melphalan/HDS was developed by Delcath Systems as a targeted, whole organ therapy for the liver. The product is commercially available in Europe under the trade name CHEMOSA... 
Printer Friendly Version
03/29/17Delcath Announces 2016 Financial Results
NEW YORK, March 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the 12 months ended December 31, 2016. Highlights for the fourth quarter of 2016 and recent weeks include: Fourth quarter 2016 revenue increased 54.0% to $0.7 million and full year 2016 revenue increased 18% to $2.0 million; Fully established national reimbursement covera... 
Printer Friendly Version
03/27/17Delcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With Melphalan/HDS in Intrahepatic Cholangiocarcinoma
Company Plans to file 2016 Fourth Quarter and Year End Financial Results by March 30, 2017 NEW YORK, March 27, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has reached a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of Delcath’s pivotal trial of Melphalan Hydrochloride for Injection for use with the Del... 
Printer Friendly Version
03/10/17Delcath Systems To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 13, 2017
NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath will be a featured presenter at the ROTH Capital Partners 29th Annual Growth Stock Conference on Monday, March 13, 2017 at 7:30 AM Pacific Time in BLUE - SALON 2 at the Ritz-Carlton Laguna Niguel, CA. Dr... 
Printer Friendly Version
02/22/17Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies
Single-Center Retrospective Data Also Demonstrate Therapy Extends Progression-Free Survival by 9 Months NEW YORK, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced today that the American Journal of Clinical Oncology has published a single-center retrospective review, in which authors found that investigational PHP with Melphalan/HDS offers promising results with... 
Printer Friendly Version
02/21/17Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential of Delcath Investigational PHP Therapy
Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders NEW YORK, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that a retrospective, multicenter study demonstrated that 45.7 percent of patients with ocular melanoma that metastasized to the liver ... 
Printer Friendly Version
02/06/17Delcath Systems to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
NEW YORK, NY / ACCESSWIRE / February 6, 2017 / Delcath Systems, Inc. (NASDAQ - DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announced today that it will be presenting at the 2nd annual Disruptive Growth & Healthcare Conference on Wednesday, February 15, 2017 at 11:15 AM EST. Delcath President & Chief Executive Officer Dr. Jennifer K. Simpson will be presenting, as well as meeting with investors.The 2017 Disruptive... 
Printer Friendly Version
01/23/17Delcath Systems To Present At The NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference On January 31, 2017
NEW YORK, Jan. 23, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath will be a featured presenter at the NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida, on Tuesday, January 31, 2017 at 10:30 am E... 
Printer Friendly Version
01/18/17New Outcomes Data Using Delcath's Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To The Liver Accepted For Oral Presentation At Regional Cancer Therapies Symposium
NEW YORK, Jan. 18, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that new data from a retrospective study of Melphalan/HDS, entitled "Percutaneous Hepatic Perfusion For Unresectable Metastatic Ocular Melanoma To The Liver: A Multi-Institutional Report Of Outcomes," has been accepted for oral presentation at the Regional Cancer Therapies 12th International Symposium, t... 
Printer Friendly Version
01/12/17Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort
Company Accepts Invitation from Cholangiocarcinoma Foundation to Present Initial Signals in ICC NEW YORK, Jan. 12, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that patient treatment and data collection for the intrahepatic cholangiocarcinoma (ICC) cohort of its European Phase 2 HCC/ICC study is ongoing, and that the Company will announce interim results for the cohor... 
Printer Friendly Version